They really only updated the market for the patient who had a CR, which is uncommon for a P1 trial.
bear in mind these patients in the final single dose cohort were average 5.5 lines of therapy so the response will be understandably muted vs the earlier cohorts.
Research/Valuation, page-515
-
- There are more pages in this discussion • 82 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.03 |
Change
-0.270(4.29%) |
Mkt cap ! $1.899B | |||
| Open | High | Low | Value | Volume |
| $6.30 | $6.45 | $5.65 | $13.43M | 2.223M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 14784 | $5.96 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.04 | 4000 | 2 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |